Alligator Bioscience’s rights issue oversubscribed
Alligator Bioscience AB (publ) (“Alligator” or the “Company”) has completed the share issue with pre-emption rights for the Company’s shareholders, which was resolved upon by the Board of Directors on December 15, 2020 pursuant to the authorization from the annual general meeting on May 5, 2020 (the “Rights Issue”). The subscription period ran from and including January 11, 2021 to and including January 25, 2021. Through the Rights Issue, Alligator receives approximately SEK 86 million before deduction of issue costs. 13 895 925 shares, corresponding to approximately 97 per cent of the Rights